Tofacitinib as a biologic response modifier in VEXAS syndrome: A case series

Int J Rheum Dis. 2023 Nov;26(11):2340-2343. doi: 10.1111/1756-185X.14785. Epub 2023 Jun 19.

Authors

Tania Salehi¹, Alicia Callisto^{1

2}, Mark Brian Beecher², Pravin Hissaria^{1

2}

Affiliations

¹ Central Adelaide Local Health Network, Adelaide, South Australia, Australia.
² Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia.

PMID: 37337622
DOI: 10.1111/1756-185X.14785

No abstract available

Publication types

Letter

MeSH terms

Humans
Immunologic Factors
Mutation
Piperidines* / adverse effects
Pyrimidines* / adverse effects

Substances

tofacitinib
Piperidines
Pyrimidines
Immunologic Factors

Supplementary concepts

VEXAS syndrome